Potential use of bitter melon (Momordica charantia) derived compounds as antidiabetics: In silico and in vivo studies.

@article{Elekofehinti2018PotentialUO,
  title={Potential use of bitter melon (Momordica charantia) derived compounds as antidiabetics: In silico and in vivo studies.},
  author={Olusola Olalekan Elekofehinti and Esther Ariyo and Moses Orimoloye Akinjiyan and Olanrewaju Sam Olayeriju and Akeem O. Lawal and Isaac Gbadura Adanlawo and Jo{\~a}o Batista T Rocha},
  journal={Pathophysiology : the official journal of the International Society for Pathophysiology},
  year={2018},
  volume={25 4},
  pages={
          327-333
        }
}

The chemical and pharmacological basis of bitter melon (Momordica charantia L.) as a potential therapy for type 2 diabetes and obesity

  • S. Habtemariam
  • Biology
    Medicinal Foods as Potential Therapies for Type-2 Diabetes and Associated Diseases
  • 2019

Antisickling potential of compounds derived from Detarium microcarpum (Fabaceae): in vitro and in silico studies

TLDR
In vitro antisickling properties of D. microcarpum stem bark was evaluated using blood samples obtained from thirty-five confirmed sickle cell disease patients using standard microscopic techniques and showed inhibited sickling of red blood cells with a laudable mean difference compared to p-hydrozybenzoic acid, which is a pure compound.

Kuguacin: biological activities of triterpenoid from Momordica charantia—a scoping review

TLDR
This study highlighted the Kuguacin, a triterpenoid isolated from any M. charantia parts, which has reported the anti-diabetic, anti-cancer,anti-influenza,Anti-HIV, and anti-tuberculosis activities of the Kugaacin.

Effects of Momordica Charantia Silver Nanoparticles on the expressions of Genes Associated With Lipid Metabolism and Nephrotoxicity in Streptozotocin-Induced Rats

TLDR
M. charantia silver nanoparticles could be a potent antidiabetic agent due to its potential to modulate genes associated with lipid metabolism and nephrotoxicity.

Effects of Bitter Melon and a Chromium Propionate Complex on Symptoms of Insulin Resistance and Type 2 Diabetes in Rat Models

TLDR
It was found that neither Cr(III) nor BM was able to significantly affect blood indices in HF and diabetic rats, but BM tended to improve body mass gain, blood glucose, and LDL cholesterol values, but decreased Cr content in the liver and kidneys of the Cr-co-supplemented type 2 diabetic model of rats.

Molecular Docking and Simulation Studies of Antidiabetic Agents Devised from Hypoglycemic Polypeptide-P of Momordica charantia

TLDR
This study was designed to use computational methods to discover the best antidiabetic peptides devised from hypoglycemic polypeptide-P of M. charantia as these ligands strongly fulfilled the drug-like evaluation criterion and proved to have good antidi diabetic properties.

Momordica charantia nanoparticles potentiate insulin release and modulate antioxidant gene expression in pancreas of diabetic rats

  • O. Elekofehinti
  • Biology, Chemistry
    Egyptian Journal of Medical Human Genetics
  • 2022
TLDR
Momordica charantia nanoparticles exhibited potential antidiabetic activity in the rat model of diabetes and thus may serve as a therapeutic agent that could be developed for medical applications in the future.

Antihyperglycaemia and related gene expressions of aqueous extract of Gongronema latifolium leaf in alloxan-induced diabetic rats

TLDR
It can be deduced that the aqueous extract of G. latifolium leaf at these doses may be useful in managing diabetes mellitus and its associated complications and may be a potent antidiabetic agent in clinical therapy in the future.

References

SHOWING 1-10 OF 17 REFERENCES

Flavonoid-rich extract of Chromolaena odorata modulate circulating GLP-1 in Wistar rats: computational evaluation of TGR5 involvement

TLDR
The results of this study support that C. odorata flavonoids may modulate the expression of GLP-1 and its release via TGR5, and may underscore its anti-diabetic potency.

Antihyperglycaemia and related gene expressions of aqueous extract of Gongronema latifolium leaf in alloxan-induced diabetic rats

TLDR
It can be deduced that the aqueous extract of G. latifolium leaf at these doses may be useful in managing diabetes mellitus and its associated complications and may be a potent antidiabetic agent in clinical therapy in the future.

Nutritional and chemical evaluation of Momordica charantia

Momordica charantia is used for some medicinal purposes in traditional medicine. The nutritional and chemical compositions of M. charantia were investigated using standard analytical methods. The

OL3, a novel low-absorbed TGR5 agonist with reduced side effects, lowered blood glucose via dual actions on TGR5 activation and DPP-4 inhibition

TLDR
OL3 is a low-absorbed TGR5 agonist that lowers blood glucose without inducing gallbladder filling and is a new strategy in the development of potent T GR5 agonists in treating type 2 diabetes, which target to the intestine to avoid systemic side effects.

A Novel TGR5 Activator WB403 Promotes GLP-1 Secretion and Preserves Pancreatic β-Cells in Type 2 Diabetic Mice

TLDR
It is demonstrated that TGR5 activator WB403 effectively promoted GLP-1 release, improved hyperglycemia and preserved the mass and function of pancreatic β-cells, whereas it did not show a significant side effect on gallbladder.

Molecular and cellular aspects of the glucagon receptor: role in diabetes and metabolism.

TLDR
With the cloning of the coding sequences, genetic manipulations of theGR should provide specific indications of the normal metabolic effects of the GR system on these tissues and how altered glucagon signalling might contribute to the development of diabetes.